Intervention Review

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

  1. Kenneth Jaaback1,*,
  2. Nick Johnson2,
  3. Theresa A Lawrie3

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 9 NOV 2011

Assessed as up-to-date: 26 SEP 2011

DOI: 10.1002/14651858.CD005340.pub3

How to Cite

Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD005340. DOI: 10.1002/14651858.CD005340.pub3.

Author Information

  1. 1

    Hunter New England Centre for Gynaecological Cancer, Ward K3 John Hunter Hospital, Newcastle, New South Wales, Australia

  2. 2

    Royal United Hospital NHS Trust, Gynaecological Oncology, Bath, UK

  3. 3

    Royal United Hospital, Cochrane Gynaecological Cancer Group, Bath, UK

*Kenneth Jaaback, Ward K3 John Hunter Hospital, Hunter New England Centre for Gynaecological Cancer, Locked Bag 1, Hunter Regional Mail Centre, Newcastle, New South Wales, 2310, Australia. Kenneth.Jaaback@hnehealth.nsw.gov.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 9 NOV 2011

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Patrick Teefey, Nadim Bou Zgheib, Sachin M. Apte, Jesus Gonzalez-Bosquet, Patricia L. Judson, William S. Roberts, Johnathan M. Lancaster, Robert M. Wenham, Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers, American Journal of Obstetrics and Gynecology, 2013, 208, 6, 501.e1

    CrossRef

  2. 2
    A. González Martín, A. Redondo, M. Jurado, A. De Juan, I. Romero, I. Bover, J. M. Del Campo, A. Cervantes, Y. García, J. A. López-Guerrero, C. Mendiola, J. Palacios, M. J. Rubio, A. Poveda Velasco, GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012, Clinical and Translational Oncology, 2013, 15, 7, 509

    CrossRef

  3. 3
    Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, Fumiaki Takahashi, Hirofumi Michimae, Eizo Kimura, Daisuke Aoki, Toshiko Jobo, Shoji Kodama, Fumitoshi Terauchi, Toru Sugiyama, Kazunori Ochiai, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, The Lancet Oncology, 2013, 14, 10, 1020

    CrossRef